Byrd v. Janssen Pharm., Inc.

Decision Date21 September 2018
Docket Number1:14-CV-0820 (GTS/DJS)
Citation333 F.Supp.3d 111
Parties Shaquil BYRD, Plaintiff, v. JANSSEN PHARM., INC.; and Johnson & Johnson, Defendants.
CourtU.S. District Court — Northern District of New York

DeGRAFF, FOY & KUNZ, LLP, Counsel for Plaintiff, 41 State Street, Albany, NY 12207, LUKE S. MALAMOOD, ESQ., GEORGE J. SZARY, ESQ.

PATTERSON, BELKNAP, WEBB & TYLER, LLP, Counsel for Defendants, 1133 Avenue of the Americas, New York, NY 10036, JOHN D. WINTER, ESQ., THOMAS P. KURLAND, ESQ., JEFFREY J. HUGHES, ESQ.

DECISION and ORDER

GLENN T. SUDDABY, Chief United States District Judge

Currently before the Court, in this products liability action filed by Shaquil Byrd ("Plaintiff") against Janssen Pharmaceuticals, Inc. ("Janssen"), and Johnson & Johnson ("Defendants"), is Defendants' motion for judgment as a matter of law pursuant to Fed. R. Civ. P. 50 or, in the alternative, for a new trial pursuant to Fed. R. Civ. P. 59. (Dkt. No. 199.) For the reasons set forth below, Defendants' motion is granted.

TABLE OF CONTENTS

I. RELEVANT BACKGROUND ...115
A. Relevant Procedural History ...115
B. Parties' Briefing on Defendants' Motion Generally ...115
II. GOVERNING LEGAL STANDARDS ...116
A. Legal Standard Governing Motions for Judgment Notwithstanding the Verdict Pursuant to Fed. R. Civ. P. 50(b) ...116
B. Legal Standard Governing Motions for a New Trial Pursuant to Fed. R. Civ. P. 59(a)...116
C. Legal Standards Governing Grounds Asserted by Defendants ...117
III. ANALYSIS ...117
A. Whether Defendants Are Entitled to Judgment as a Matter of Law Because Plaintiff's Failure-to-Warn Claim Is Preempted ...117
B. Whether Defendants Are Entitled to Judgment as a Matter of Law for the Alternative Reason that Plaintiff Failed to Introduce Sufficient Evidence of Proximate and Medical Causation ...125
C. Whether, in the Alternative, Defendants Are Entitled to a New Trial Because of the Conduct of Plaintiff's Counsel ...131
D. Remaining Issues (I.e., Whether Plaintiff Cannot Establish that Defendant Johnson & Johnson Is Liable as a Matter of Law, Whether the Jury Verdict Is Against the Weight of the Evidence, and Whether Plaintiff's Award Is Excessive )...135
I. RELEVANT BACKGROUND
A. Relevant Procedural History

Generally, following the issuance of the Court's Decision and Order of March 7, 2017, two claims of Plaintiff's Amended Complaint survived Defendants' motion for summary judgment: (1) Plaintiff's claim that Defendants were negligent in designing, manufacturing, and selling Risperdal

as well as in failing to properly warn the general public of the risks and dangers of Risperdal ; and (2) Plaintiff's claim that Defendants are strictly liable for the injuries caused by (a) Risperdal's defective condition, (b) the failure to give appropriate warnings regarding the drug's dangers and adverse effects, and (c) their misleading representations regarding the risk of gynecomastia and hyperprolactinemia in adolescent patients. (Dkt. No. 108, at 70.)

The trial on these two claims commenced on September 18, 2017. (Dkt. No. 163.) At the conclusion of the trial on September 27, 2017, the jury reached a verdict against Plaintiff with regard to his negligent design claim but in favor of him with regard to his failure-to-work claim, awarding him $500,000 for past and/or present pain and suffering and $500,000 in future pain and suffering; and Judgment was entered accordingly. (Dkt. Nos. 179, 180.) On October 25, 2017, Defendants filed the current motion for judgment a matter of law pursuant to Fed. R. Civ. P. 50 or, in the alternative, for a new trial pursuant to Fed. R. Civ. P. 59. (Dkt. No. 199.) Plaintiff has opposed this motion. (Dkt. No. 204, 205.)

Because this Decision and Order is intended primarily for the review of the parties, who have (in their memoranda of law) demonstrated an accurate understanding of the remainder of the relevant procedural history of this action, the Court will not summarize the remainder of that procedural history in detail in this Decision and Order.

B. Parties' Briefing on Defendants' Motion Generally

Generally, in their motion, Defendants assert the following arguments: (1) as a threshold matter, Defendant Janssen is entitled to judgment as a matter of law because (a) Plaintiff's failure-to-warn claim is preempted by federal law, (b) Plaintiff failed to introduce sufficient evidence of proximate and medical causation, and (c) Plaintiff cannot establish that Defendant Johnson & Johnson is liable; and (2) in the alternative, Defendant Janssen is entitled to a new trial because (a) the jury's verdict is against the weight of the evidence, (b) the conduct of Plaintiff's counsel warrants a new trial, and (c) Plaintiff's award is excessive (warranting either remittitur or a new trial). (Dkt. No. 199, Attach. 1.)

Generally, in opposition to Defendants' motion, Plaintiff asserts the following arguments: (1) Defendants are not entitled to judgment as a matter of law because (a) their preemption arguments are meritless, unavailing and frivolous, (b) their arguments regarding causation are similarly unavailing and (c) Defendant Johnson & Johnson is liable just as Defendant Janssen is liable; and (2) there is no legal basis warranting a new trial because (a) the verdict is supported by compelling evidence, (b) there is no evidence of prejudice against Defendants created by the actions of Plaintiff's counsel, and (c) Plaintiff's award is not excessive but is comparable to awards in identical cases. (Dkt. No. 205.)

Generally, in reply, Defendants repeat the arguments asserted in their memorandum of law-in chief, albeit modified to reply to Plaintiff's responses. (Dkt. No. 206.)

II. GOVERNING LEGAL STANDARDS
A. Legal Standard Governing Motions for Judgment Notwithstanding the Verdict Pursuant to Fed. R. Civ. P. 50(b)

Rule 50(b) of the Federal Rules of Civil Procedure provides as follows, in pertinent part:

If the court does not grant a motion for judgment as a matter of law made under Rule 50(a), the court is considered to have submitted the action to the jury subject to the court's later deciding the legal questions raised by the motion. No later than 28 days after the entry of judgment—or if the motion addresses a jury issue not decided by a verdict, no later than 28 days after the jury was discharged—the movant may file a renewed motion for judgment as a matter of law and may include an alternative or joint request for a new trial under Rule 59.

Fed. R. Civ. P. 50(b) (emphasis added).

As a result, a prerequisite for a motion for a post-trial motion for a judgment as a matter of law (also known as a motion for judgment notwithstanding the verdict) is a pre-verdict motion for judgment as a matter of law. See Fed. R. Civ. P. 50 Advisory Committee Note (1963) ("A motion for judgment notwithstanding the verdict will not lie unless it was preceded by a motion for a judgment as a matter of law made at the close of all the evidence.") (emphasis added); Fed. R. Civ. P. 50 Advisory Committee Note (1991) ("A post-trial motion for judgment can be granted only on grounds advanced in the pre-verdict motion."); Exxon Shipping Co. v. Baker , 554 U.S. 471, 486, n.5, 128 S.Ct. 2605, 171 L.Ed.2d 570 (2008) ("A motion under Rule 50(b) is not allowed unless the movant sought relief on similar grounds under Rule 50(a) before the case was submitted to the jury.").

Such a post-trial motion may be granted by a district court where doing so is necessary to prevent "manifest injustice." Kirsch v. Fleet Street, Ltd. , 148 F.3d 149, 164 (2d Cir. 1998) ("As to any issue on which proper Rule 50 motions were not made, [a judgment as a matter of law] may not properly be granted by the district court, or upheld on appeal, or ordered by the appellate court unless that action is required in order to prevent manifest injustice."); accord , Lore v. City of Syracuse , 670 F.3d 127, 153 (2d Cir. 2012) ; Cordius Trust v. Kummerfeld , 331 F. App'x 810, 811 (2d Cir. 2009). "[M]anifest justice" exists only when a jury's verdict is "wholly without legal support." Pahuta v. Massey-Ferguson, Inc. , 170 F.3d 125, 129 (2d Cir. 1999) ("We may overlook such a default in order to ‘prevent a manifest injustice’ in cases where a jury's verdict is wholly without legal support.") (internal quotation marks omitted); accord, U.S. S.E.C. v. Stamoulis , 350 F. App'x 499, 500 (2d Cir. 2009) ; Clergeau v. Local 1181, Amalgamated Transit Union, AFL-CIO , 162 F. App'x 32, 34 (2d Cir. 2005) ; Rothstein v. Carriere , 373 F.3d 275, 291 (2nd Cir. 2004).

B. Legal Standard Governing Motions for a New Trial Pursuant to Fed. R. Civ. P. 59(a)

Rule 59(a) of the Federal Rules of Civil Procedure provides, in pertinent part, that "[t]he court may, on motion, grant a new trial on all or some of the issues–and to any party– ... after a jury trial, for any reason for which a new trial has heretofore been granted in an action at law in federal court ...." Fed. R. Civ. P. 59(a)(1)(A). The Second Circuit has interpreted this standard to permit the granting of new trials when, "in the opinion of the district court, the jury has reached a seriously erroneous result or the verdict is a miscarriage of justice." DLC Mgmt. Corp. v. Town of Hyde Park , 163 F.3d 124, 133 (2d Cir. 1998) (internal quotation marks omitted); Lightfoot v. Union Carbide Corp. , 110 F.3d 898, 911 (2d Cir. 1997). Examples of such a serious error or a miscarriage of justice include when "the verdict is against the weight of the evidence," or when "for the reasons stated the trial was not fair to the moving party." Mallis v. Bankers Trust Co. , 717 F.2d 683, 691 (2d Cir. 1983). However, "the court should only grant a ...

To continue reading

Request your trial
6 cases
  • Holley v. Gilead Scis., Inc., Case No. 18-cv-06972-JST
    • United States
    • U.S. District Court — Northern District of California
    • May 10, 2019
    ...relevant question is whether the plaintiff's physician would have "prescribed the drug in the same manner. " Byrd v. Janssen Pharm., Inc. , 333 F.Supp.3d 111, 127 (N.D.N.Y. 2018) (emphasis added) (quoting Alston v. Caraco Pharm., Inc. , 670 F.Supp.2d 279, 285 (S.D.N.Y. 2009) ). Thus, for ex......
  • McGrath v. Bayer Healthcare Pharm. Inc.
    • United States
    • U.S. District Court — Eastern District of New York
    • June 24, 2019
    ...or (2) by presenting clear evidence that the FDA would not have approved a change to the drug's label." Byrd v. Janssen Pharm, Inc., 333 F. Supp. 3d 111, 120 (N.D.N.Y. 2018) (emphasis added) (citing Amos v. Biogen Idec Inc., 249 F. Supp. 3d 690, 699 (W.D.N.Y. 2017) )."Newly acquired informa......
  • Cleveland v. Janssen Pharm.
    • United States
    • U.S. District Court — Eastern District of California
    • November 15, 2019
    ...to plaintiff in April 2015. Id. at 55:8-56:19. The FDA has characterized gynecomastia as a nonserious risk. Byrd v. Janssen Pharm., Inc., 333 F.Supp.3d 111, 124 (N.D.N.Y. 2018); November 25, 2014 Letter from Dr. Janet Woodcock to Stephen Sheller, Ex. 24 to Barkeshli Decl., at 7. Plaintiff h......
  • Bayless v. Bos. Sci. Corp.
    • United States
    • U.S. Court of Appeals — Eleventh Circuit
    • February 2, 2023
    ... ... See Kilpatrickv. Breg, Inc. , 613 F.3d 1329 (11th ... Cir. 2010); McClain v. Metabolife Int'l, ... [ 9 ] Coloplast also cites Byrdv ... Janssen ... ...
  • Request a trial to view additional results

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT